Can Lupin use oseltamivir approval to deepen its China respiratory medicine strategy?
Lupin’s China approval adds a paediatric-friendly flu antiviral to its portfolio. See why formulation and access still matter in generics.
Can AeroRx turn nebulized COPD treatment into a first-line dual bronchodilator category?
COPD care relies on handheld inhalers, but many patients struggle with delivery. AeroRx is testing whether nebulized dual therapy can close that gap.
What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition
Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.
What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Mabwell’s anti-ST2 antibody 9MW1911 cleared for U.S. Phase IIa trial: Could this reshape COPD biologics?
Mabwell Biopharmaceuticals has received Investigational New Drug (IND) clearance from the United States Food and Drug Administration to initiate a Phase IIa clinical study for its anti-ST2 monoclonal antibody, 9MW1911, in patients with moderate-to-severe chronic obstructive pulmonary disease. This regulatory milestone comes on the heels of a completed Phase IIa study in China, where Mabwell […]